Thus, dual capacity of induction of mucosal IgA responses and protection against viral infection should be taken into consideration when selecting detoxified TLR3 agonist as safe anti-infectious vaccine adjuvants for human use.27 The gene discussed is CD79A; the disease is viral infectious disease.